Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins

Journal of Pharmaceutical Sciences

Volumn 104, Issue 6, 2015, Pages 1866-1884

  Liu, Liming ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ADCC; biosimilar; CDC; Fc fusion; glycosylation; immunogenicity; mAb; pharmacodynamics; pharmacokinetics

Indexed keywords

AMINO ACID; BIOSIMILAR AGENT; FC RECEPTOR; FC RECEPTOR IIIA; FUCOSE; GALACTOSE; GLYCAN DERIVATIVE; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MANNOSE; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; N ACETYLNEURAMINIC ACID; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; POLYSACCHARIDE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHO CELL LINE; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GENE EXPRESSION SYSTEM; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; ANIMAL; CARBOHYDRATE ANALYSIS; CHEMISTRY; MOLECULAR GENETICS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CARBOHYDRATE SEQUENCE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; RECOMBINANT FUSION PROTEINS;

EID: 84929154056     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24444     Document Type: Review

References (184)

1. Kohler G, Milstein C,. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
2. Smith SL,. 1996. Ten years of orthoclone OKT3 (muromonab-CD3): A review. J Transpl Coord 6: 109-119.
3. Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, O'Connell JB, Stuart F, McDiarmid SV, Wall W,. 1995. The OKT3 antibody response study: A multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol 3: 212-221.
4. Sgro C,. 1995. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review. Toxicology 105: 23-29.
5. Siegel JP,. 1997. Rituximab approval letter. FDA 97-0244.
6. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaia N,. 2008. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 9: 482-501.
7. Elvin JG, Couston RG, van der Walle CF,. 2013. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int J Pharm 440: 83-98.
8. Ju MS, Jung ST,. 2014. Aglycosylated full-length IgG antibodies: Steps toward next-generation immunotherapeutics. Curr Opin Biotechnol 30C: 128-139.
9. Jefferis R,. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21: 11-16.
10. Pennica D, Lam VT, Weber RF, Kohr WJ, Basa LJ, Spellman MW, Ashkenazi A, Shire SJ, Goeddel DV,. 1993. Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry 32: 3131-3138.
11. Stefanich EG, Ren S, Danilenko DM, Lim A, Song A, Iyer S, Fielder PJ,. 2008. Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins. J Pharmacol Exp Ther 327: 308-315.
12. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P,. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325: 979-989.
13. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA,. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25: 21-50.
14. Nimmerjahn F, Ravetch JV,. 2012. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 12: 13.
15. Tao MH, Morrison SL,. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143: 2595-2601.
16. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD,. 2008. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA 105: 20167-20172.
17. Liu L, Gomathinayagam S, Hamuro L, Prueksaritanont T, Wang W, Stadheim TA, Hamilton SR,. 2013. The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in glycoengineered pichia pastoris. Pharm Res 30: 803-812.
18. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC,. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21: 949-959.
19. rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 108, ASH Annual Meeting Abstracts #229.
20. Goede V, Fischer K, Busch Rea. 2013. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil versus rituximab plus chlorambucil in patients with chronic lymphocytic leukemia and co-existing medical conditions (comorbidities). Blood 122, ASH Annual Meeting Abstracts #6.
21. FDA. 2012. Guidance for industry biosimilars: Questions and answers regarding implementation of the biologics price competition and innovation act of 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM273001.pdf
22. FDA. 2012. Guidance for industry scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf
23. FDA. 2012. Guidance for industry quality considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
24. FDA. 2014. Guidance for industry clinical pharmacology data to support a demonstration of biosimilarity to a reference product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf
25. EMEA. 2014. EMEA guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues. http://www.ebe-biopharma.eu/uploads/Modules/Newsroom/ema:chmp:bwp:247713:2012.pdf
26. EMEA. 2014. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf
27. Jefferis R., 2009. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30: 356-362.
28. Hayes JM, Cosgrave EF, Struwe WB, Wormald M, Davey GP, Jefferis R, Rudd PM,. 2014. Glycosylation and Fc receptors. Curr Top Microbiol Immunol 382: 165-199.
29. Kornfeld R, Keller J, Baenziger J, Kornfeld S,. 1971. The structure of the glycopeptide of human gamma G myeloma proteins. J Biol Chem 246: 3259-3268.
30. Kornfeld R, Kornfeld S,. 1976. Comparative aspects of glycoprotein structure. Annu Rev Biochem 45: 217-237.
31. Kornfeld R, Kornfeld S,. 1985. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54: 631-664.
32. Allen AC, Harper SJ, Feehally J,. 1995. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 100: 470-474.
33. Strasser R., 2012. Challenges in O-glycan engineering of plants. Front Plant Sci 3: 218.
34. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA,. 2012. Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22: 736-756.
35. Wopereis S, Lefeber DJ, Morava E, Wevers RA,. 2006. Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: A review. Clin Chem 52: 574-600.
36. Tarp MA, Clausen H,. 2008. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780: 546-563.
37. Raju TS, Briggs JB, Borge SM, Jones AJ,. 2000. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10: 477-486.
38. Raju TS,. 2003. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. BioProcess Int: 44-53.
39. Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL,. 2002. Myeloma expression systems. J Immunol Methods 261: 1-20.
40. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K,. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 3466-3473.
41. Beck A, Cochet O, Wurch T,. 2010. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin Drug Discov 5: 95-111.
42. Gerngross TU,. 2004. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22: 1409-1414.
43. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi BK, Cook WJ, Cukan M, Houston-Cummings NR, Davidson R, Gong B, Hamilton SR, Hoopes JP, Jiang Y, Kim N, Mansfield R, Nett JH, Rios S, Strawbridge R, Wildt S, Gerngross TU,. 2006. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24: 210-215.
44. Durocher Y, Butler M,. 2009. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 20: 700-707.
45. Wolfson W,. 2013. Grow your own: Protalix BioTherapeutics produces drugs in carrot cells. Chem Biol 20: 969-970.
46. Pfizer. 2012. ELELYSO US physician prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022458lbl.pdf
47. Deegan PB, Cox TM,. 2012. Imiglucerase in the treatment of Gaucher disease: A history and perspective. Drug Des Devel Ther 6: 81-106.
48. Langreth R, Chen C, Nash J, Lauerman J,. 2014. Ebola drug made from tobacco plant saves U.S. aid workers. Business Week, 08/14/2014. http://www.bloomberg.com/news/articles/2014-08-05/ebola-drug-made-from-tobacco-plant-saves-u-s-aid-workers.
49. Olinger GG Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L,. 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109: 18030-18035.
50. Wacker C, Berger CN, Girard P, Meier R,. 2011. Glycosylation profiles of therapeutic antibody pharmaceuticals. Eur J Pharm Biopharm 79: 503-507.
51. Daëron C,. 2014. Fc receptors as adaptive immunoreceptors. Curr Top Microbiol Immunol 382: 131-164.
52. Jefferis R, Lund J,. 2002. Interaction sites on human IgG-Fc for FcgammaR: Current models. Immunol Lett 82: 57-65.
53. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M,. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
54. Perussia B, Ravetch JV,. 1991. Fc gamma RIII (CD16) on human macrophages is a functional product of the Fc gamma RIII-2 gene. Eur J Immunol 21: 425-429.
55. Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umana P, Benz J,. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 108: 12669-12674.
56. Roopenian DC, Akilesh S,. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725.
57. Simister NE, Mostov KE,. 1989. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 54 Pt 1: 571-580.
58. Simister NE, Mostov KE,. 1989. An Fc receptor structurally related to MHC class I antigens. Nature 337: 184-187.
59. Shah U, Dickinson BL, Blumberg RS, Simister NE, Lencer WI, Walker WA,. 2003. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatr Res 53: 295-301.
60. Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A, Simister NE,. 1997. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92: 69-74.
61. Cianga P, Cianga C, Cozma L, Ward ES, Carasevici E,. 2003. The MHC class I related Fc receptor, FcRn, is expressed in the epithelial cells of the human mammary gland. Hum Immunol 64: 1152-1159.
62. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, Ghetie V, Ward ES,. 1998. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol 10: 1289-1298.
63. Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL,. 2006. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 290: G352-G360.
64. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE,. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology 89: 573-578.
65. Ghetie V, Ward ES,. 1997. FcRn: The MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18: 592-598.
66. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL,. 2003. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197: 315-322.
67. Simister NE, Story CM,. 1997. Human placental Fc receptors and the transmission of antibodies from mother to fetus. J Reprod Immunol 37: 1-23.
68. Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, Ghetie V, Ward ES,. 2001. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 13: 993-1002.
69. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, Lencer WI, Blumberg RS,. 2004. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20: 769-783.
70. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, Claypool SM, Kaser A, Nagaishi T, Higgins DE, Mizoguchi E, Wakatsuki Y, Roopenian DC, Mizoguchi A, Lencer WI, Blumberg RS,. 2006. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 116: 2142-2151.
71. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS,. 2008. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 105: 9337-9342.
72. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G,. 2012. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 7: 1596-1602.
73. Alsenaidy MA, Kim JH, Majumdar R, Weis DD, Joshi SB, Tolbert TJ, Middaugh CR, Volkin DB,. 2013. High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation. J Pharm Sci 102: 3942-3956.
74. Alsenaidy MA, Okbazghi SZ, Kim JH, Joshi SB, Middaugh CR, Tolbert TJ, Volkin DB,. 2014. Physical stability comparisons of IgG1-Fc variants: Effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297. J Pharm Sci 103: 1613-1627.
75. Feige MJ, Nath S, Catharino SR, Weinfurtner D, Steinbacher S, Buchner J,. 2009. Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol 391: 599-608.
76. Nose M, Wigzell H,. 1983. Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA 80: 6632-6636.
77. Kim JK, Tsen MF, Ghetie V, Ward ES,. 1994. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 24: 542-548.
78. Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, Hochman J, Prueksaritanont T,. 2011. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO produced materials. Biologicals 39: 205-210.
79. Clarke S, Gebbie C, Sweeney C, Olszewksi N, Smith J,. 2009. A phase I, pharmacokinetic (PK) and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol 27: 15s, (suppl; abstr3025).
80. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA,. 2014. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res 20: 1666-1675.
81. Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S,. 2013. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol 53: 1103-1111.
82. Hobbs SM, Jackson LE, Hoadley J,. 1992. Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: Comparison of deglycosylation by tunicamycin treatment and genetic engineering. Mol Immunol 29: 949-956.
83. Kim JK, Tsen MF, Ghetie V, Ward ES,. 1994. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol 24: 2429-2434.
84. Kim JK, Tsen MF, Ghetie V, Ward ES,. 1994. Catabolism of the murine IgG1 molecule: Evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. Scand J Immunol 40: 457-465.
85. Ashwell G, Harford J,. 1982. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51: 531-554.
86. Mi Y, Lin A, Fiete D, Steirer L, Baenziger JU,. 2014. Modulation of mannose and asialoglycoprotein receptor expression determines glycoprotein hormone half-life at critical points in the reproductive cycle. J Biol Chem 289: 12157-12167.
87. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M,. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17: 104-118.
88. Wright A, Morrison SL,. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 180: 1087-1096.
89. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S,. 2000. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10: 1347-1355.
90. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R,. 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4: 475-487.
91. Winkelhake JL, Nicolson GL,. 1976. Aglycosylantibody. Effects of exoglycosidase treatments on autochthonous antibody survival time in the circulation. J Biol Chem 251: 1074-1080.
92. Bailey MJ, Hooker AD, Adams CS, Zhang S, James DC,. 2005. A platform for high-throughput molecular characterization of recombinant monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 826: 177-187.
93. Chen X, Flynn GC,. 2007. Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry. Anal Biochem 370: 147-161.
94. Kamoda S, Ishikawa R, Kakehi K,. 2006. Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. J Chromatogr A 1133: 332-339.
95. Flynn GC, Chen X, Liu YD, Shah B, Zhang Z,. 2010. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol 47: 2074-2082.
96. Chen X, Liu YD, Flynn GC,. 2009. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 19: 240-249.
97. Naso MF, Tam SH, Scallon BJ, Raju TS,. 2010. Engineering host cell lines to reduce terminal sialylation of secreted antibodies. MAbs 2: 519-527.
98. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS,. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44: 1524-1534.
99. Youings A, Chang SC, Dwek RA, Scragg IG,. 1996. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J 314 (Pt 2): 621-630.
100. Huang L, Biolsi S, Bales KR, Kuchibhotla U,. 2006. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Anal Biochem 349: 197-207.
101. Coloma MJ, Trinh RK, Martinez AR, Morrison SL,. 1999. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1->6) dextran antibody. J Immunol 162: 2162-2170.
102. Beck A, Reichert JM,. 2011. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3: 415-416.
103. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T,. 2010. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184: 1968-1976.
104. Suen KF, Turner MS, Gao F, Liu B, Althage A, Slavin A, Ou W, Zuo E, Eckart M, Ogawa T, Yamada M, Tuntland T, Harris JL, Trauger JW,. 2010. Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure. Protein Expr Purif 71: 96-102.
105. Flesher AR, Marzowski J, Wang WC, Raff HV,. 1995. Fluorophore-labeled carbohydrate analysis of immunoglobulin fusion proteins: Correlation of oligosaccharide content with in vivo clearance profile. Biotechnol Bioeng 47: 405.
106. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS,. 1995. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 2: 159-171.
107. Kim HJ, Kim HJ,. 2007. The glycosylation and pharmacokinetics of CTLA4Ig produced in rice cells. Biol Pharm Bull 30: 1913-1917.
108. Jones AJ, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, Kneer J, Battersby JE,. 2007. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17: 529-540.
109. Keck R, Nayak N, Lerner L, Raju S, Ma S, Schreitmueller T, Chamow S, Moorhouse K, Kotts C, Jones A,. 2008. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 36: 49-60.
110. Schwartz AL,. 1991. Trafficking of asialoglycoproteins and the asialoglycoprotein receptor. Targeted Diagn Ther 4: 3-39.
111. Williams RC Jr, Osterland CK, Margherita S, Tokuda S, Messner RP,. 1973. Studies of biologic and serologic activities of rabbit-IgG antibody depleted of carbohydrate residues. J Immunol 111: 1690-1698.
112. Koide N, Nose M, Muramatsu T,. 1977. Recognition of IgG by Fc receptor and complement: Effects of glycosidase digestion. Biochem Biophys Res Commun 75: 838-844.
113. Rothman RJ, Perussia B, Herlyn D, Warren L,. 1989. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol Immunol 26: 1113-1123.
114. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG,. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740.
115. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M,. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87: 614-622.
116. Satoh M, Iida S, Shitara K,. 2006. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6: 1161-1173.
117. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K,. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336: 1239-1249.
118. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K,. 2005. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods 306: 93-103.
119. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, Kanda Y, Niwa R, Iida S, Uchida K, Shitara K, Satoh M,. 2004. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 88: 901-908.
120. Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Mori K, Inoue M, Kitajima-Miyama K, Okazaki A, Iida S, Shitara K, Satoh M,. 2007. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol 130: 300-310.
121. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R,. 2009. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 58: 1195-1206.
122. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M,. 2006. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 12: 2879-2887.
123. Hanai N, Nakamura K, Shoji E, Yamasaki M, Uchida K, Shinkawa T, Kanda T, Yamne N, Anazawa H, Imabeppu S. 2000. Method for controlling the activity of immunological functional molecule. Int. Pub. num. WO00/61739, Oct. 19, 2000.
124. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K,. 2007. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 44: 3122-3131.
125. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M,. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74: 288-294.
126. Ideda Y, Naoyuki T,. 2001. Enzymatic properties and biological functions of b1,4-N-acetylglucosaminyl transferase III. Trends Glycosci Glycotechnol 13: 167-176.
127. Hodoniczky J, Zheng YZ, James DC,. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21: 1644-1652.
128. Boyd PN, Lines AC, Patel AK,. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32: 1311-1318.
129. Peipp M, Dechant M, Valerius T,. 2008. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 20: 436-443.
130. Raju TS,. 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20: 471-478.
131. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P,. 2006. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281: 5032-5036.
132. Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y, Yano K, Shitara K, Hosoi S, Satoh M,. 2006. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng 94: 680-688.
133. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T,. 2008. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99: 652-665.
134. Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L,. 2014. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci USA 111: 5992-5997.
135. Nimmerjahn F, Ravetch JV,. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26: 513-533.
136. Anthony RM, Ravetch JV,. 2010. A novel role for the IgG Fc glycan: The anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30 (Suppl 1): S9-S14.
137. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV,. 2011. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
138. Kaneko Y, Nimmerjahn F, Ravetch JV,. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
139. Samuelsson A, Towers TL, Ravetch JV,. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
140. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV,. 2013. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA 110: 9868-9872.
141. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV,. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-376.
142. Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, Chereau C, Pagnoux C, Michalski JC, Guillevin L, Weill B, Batteux F, Guilpain P,. 2011. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 63: 2105-2115.
143. Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T,. 1988. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 167: 1731-1736.
144. Parekh R, Isenberg D, Rook G, Roitt I, Dwek R, Rademacher T,. 1989. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 2: 101-114.
145. Shade KTCARM,. 2013. Antibody glycosylation and inflammation. Antibodies 2: 392-414.
146. Shikata K, Yasuda T, Takeuchi F, Konishi T, Nakata M, Mizuochi T,. 1998. Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 15: 683-689.
147. van de Geijn FE, Wuhrer M, Selman MH, Willemsen SP, de Man YA, Deelder AM, Hazes JM, Dolhain RJ,. 2009. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: Results from a large prospective cohort study. Arthritis Res Ther 11: R193.
148. Wright A, Tao MH, Kabat EA, Morrison SL,. 1991. Antibody variable region glycosylation: Position effects on antigen binding and carbohydrate structure. EMBO J 10: 2717-2723.
149. Wallick SC, Kabat EA, Morrison SL,. 1988. Glycosylation of a VH residue of a monoclonal antibody against alpha (1 - 6) dextran increases its affinity for antigen. J Exp Med 168: 1099-1109.
150. Jacquemin M, Radcliffe CM, Lavend'homme R, Wormald MR, Vanderelst L, Wallays G, Dewaele J, Collen D, Vermylen J, Dwek RA, Saint-Remy JM, Rudd PM, Dewerchin M,. 2006. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. J Thromb Haemost 4: 1047-1055.
151. Labeta MO, Margni RA, Leoni J, Binaghi RA,. 1986. Structure of asymmetric non-precipitating antibody: Presence of a carbohydrate residue in only one Fab region of the molecule. Immunology 57: 311-317.
152. Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, Dolhain RJ, Wuhrer M,. 2014. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics 13: 3029-3039.
153. Koene HR, Kleijer M, Algra J, Roos D, dem Borne AE, de Haas M,. 1997. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90: 1109-1114.
154. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H,. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758.
155. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF,. 2005. Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16: 1675-1682.
156. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK,. 2006. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108: 2720-2725.
157. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA,. 2005. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23: 474-481.
158. Weng WK, Levy R,. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947.
159. Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S,. 2014. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an Italian multicentre study. Ann Rheum Dis 73: 716-721.
160. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A,. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796.
161. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sabourin JC, Boissiere-Michot F,. 2009. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129.
162. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE,. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17: 176-180.
163. von Horsten HH, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K, Kaup M, Berger M, Jordan I, Sandig V,. 2010. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology 20: 1607-1618.
164. Beck A, Reichert JM,. 2012. Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 4: 419-425.
165. Subramaniam JM, Whiteside G, McKeage K, Croxtall JC,. 2012. Mogamulizumab: First global approval. Drugs 72: 1293-1298.
166. Robak T., 2009. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 10: 588-596.
167. Cameron F, McCormack PL,. 2014. Obinutuzumab: First global approval. Drugs 74: 147-154.
168. Nechansky A, Kircheis R,. 2010. Immunogenicity of therapeutics: A matter of efficacy and safety. Expert Opin Drug Discov 5: 1067-1079.
169. Barbosa MD,. 2011. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 16: 345-353.
170. Lam JS, Mansour MK, Specht CA, Levitz SM,. 2005. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 175: 7496-7503.
171. Macher BA, Galili U,. 2008. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: A carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 1780: 75-88.
172. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q,. 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 364: 8-18.
173. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA,. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109-1117.
174. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM,. 2007. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25: 3644-3648.
175. Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark E, Cooper PJ, Platts-Mills TA,. 2011. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol 127: 1286-1293.
176. Commins SP, Platts-Mills TA,. 2013. Tick bites and red meat allergy. Curr Opin Allergy Clin Immunol 13: 354-359.
177. WebMD Tick Bites Linked to red meat allergy. 08/13/2014. http://www.webmd.com/allergies/news/20140813/tick-bites-red-meat-allergy
178. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X, Varki A,. 2008. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology 18: 818-830.
179. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R,. 2011. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res 71: 3352-3363.
180. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E,. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100: 12045-12050.
181. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A,. 2010. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28: 863-867.
182. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A,. 2012. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28: 147-175.
183. Bush L,. 2009. Manufacturing problems again hold up FDA approval of Genzyme's large-scale production of lumizyme. Biopaharm Int. com. http://www.biopharminternational.com/node/221503?rel=canonical
184. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R,. 2011. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29: 310-312.